BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34633087)

  • 1. Prognostic role of 11C-choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy.
    Jimbo M; Andrews JR; Ahmed ME; Dundar A; Karnes RJ; Bryce AH; Kendi AT; Kwon ED; Lowe VJ; Bold MS
    Prostate; 2022 Jan; 82(1):41-48. PubMed ID: 34633087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective evaluation of [
    Schwarzenböck SM; Eiber M; Kundt G; Retz M; Sakretz M; Kurth J; Treiber U; Nawroth R; Rummeny EJ; Gschwend JE; Schwaiger M; Thalgott M; Krause BJ
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2105-2113. PubMed ID: 27317482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiographic paradoxical response in metastatic castrate-resistant prostate cancer (mCRPC) managed with new generation anti-androgens: a retrospective analysis.
    Alamiri J; Britton CJ; Ahmed ME; Andrews JR; Higa JL; Dundar A; Karnes RJ; Kwon E; Lowe VJ; Kendi AT; Bold MS; Pagliaro LC
    Prostate; 2022 Dec; 82(16):1483-1490. PubMed ID: 36089822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Value of
    Quaquarini E; D'Ambrosio D; Sottotetti F; Gallivanone F; Hodolic M; Baiardi P; Palumbo R; Vellani C; Canevari C; Bernardo A; Castiglioni I; Porta C; Trifirò G
    Contrast Media Mol Imaging; 2019; 2019():4325946. PubMed ID: 31049043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the role of Ga-68 PSMA I&T PET/CT in response evaluation to docetaxel therapy in castration resistant prostate cancer patients.
    Özülker T; Özülker F
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(5):292-298. PubMed ID: 32595026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
    Caroli P; De Giorgi U; Scarpi E; Fantini L; Moretti A; Galassi R; Celli M; Conteduca V; Rossi L; Bianchi E; Paganelli G; Matteucci F
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):348-354. PubMed ID: 29110067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT.
    Farnebo J; Wadelius A; Sandström P; Nilsson S; Jacobsson H; Blomqvist L; Ullén A
    Medicine (Baltimore); 2016 Aug; 95(31):e4308. PubMed ID: 27495034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-Specific Membrane Antigen Expression on PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study.
    Calderoni L; Maietti E; Farolfi A; Mei R; Louie KS; Groaning M; Fanti S
    J Nucl Med; 2023 Jun; 64(6):910-917. PubMed ID: 36635087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (11)C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel.
    Ceci F; Castellucci P; Graziani T; Schiavina R; Renzi R; Borghesi M; Di Tullio P; Brunocilla E; Ardizzoni A; Fanti S
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):84-91. PubMed ID: 26323576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.
    De Giorgi U; Caroli P; Scarpi E; Conteduca V; Burgio SL; Menna C; Moretti A; Galassi R; Rossi L; Amadori D; Paganelli G; Matteucci F
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1276-83. PubMed ID: 25808631
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Shagera QA; Artigas C; Karfis I; Critchi G; Chanza NM; Sideris S; Peltier A; Paesmans M; Gil T; Flamen P
    J Nucl Med; 2022 Aug; 63(8):1191-1198. PubMed ID: 34772793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbon 11-choline positron emission tomography/computed tomography and palliative local therapy for castration-resistant prostate cancer.
    Nozaki K; Kawai T; Fujimura T; Matsui H; Teshima T; Oshina T; Takahashi A; Sato Y; Yamada D; Azuma T; Hotta M; Nakajima K; Nakayama H; Minamimoto R; Kume H
    Int Urol Nephrol; 2019 Oct; 51(10):1763-1769. PubMed ID: 31325132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with
    Telli T; Tuncel M; Karabulut E; Aksoy S; Erman M; Akdogan B; Caglar M
    Prostate; 2023 Jun; 83(8):792-800. PubMed ID: 36919876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of
    Kimura K; Kitajima K; Kawanaka Y; Yokoyama H; Komoto H; Fujiwara M; Furukawa Y; Kanematsu A; Yamamoto S; Miyake H; Yamakado K
    Int J Urol; 2022 Sep; 29(9):1072-1078. PubMed ID: 35875967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer.
    Mager R; Savko O; Böhm K; Thomas A; Dotzauer R; Borgmann H; Jäger W; Thomas C; Haferkamp A; Höfner T; Tsaur I
    Urol Oncol; 2019 Dec; 37(12):999-1005. PubMed ID: 31377168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the viability and treatment response of bone metastases in patients with metastatic castration-resistant prostate cancer using choline PET/CT.
    Kitajima K; Yamamoto S; Kawanaka Y; Komoto H; Shimatani K; Hanasaki T; Taguchi M; Nagasawa S; Yamada Y; Kanematsu A; Yamakado K
    Medicine (Baltimore); 2021 Jun; 100(23):e26206. PubMed ID: 34115004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective study on the early evaluation of response to androgen receptor-targeted agents with
    Mollica V; Marchetti A; Fraccascia N; Nanni C; Tabacchi E; Malizia C; Argalia G; Rosellini M; Tassinari E; Paccapelo A; Fanti S; Massari F
    ESMO Open; 2024 May; 9(5):103448. PubMed ID: 38718704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of 18-Fluoro-2-Deoxy-Glucose Positron Emission Tomography/Computed Tomography as Response and Prognosis Predictive Factor of Concurrent Chemoradiotherapy after Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Prospective Study.
    Šedienė S; Kulakienė I; Rudžianskas V; Ambrazienė R
    Medicina (Kaunas); 2018 May; 54(2):. PubMed ID: 30344262
    [No Abstract]   [Full Text] [Related]  

  • 20. Preliminary results on response assessment using
    Seitz AK; Rauscher I; Haller B; Krönke M; Luther S; Heck MM; Horn T; Gschwend JE; Schwaiger M; Eiber M; Maurer T
    Eur J Nucl Med Mol Imaging; 2018 Apr; 45(4):602-612. PubMed ID: 29185010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.